Switch Therapeutics Raises $52M in Series A Funding

Switch Therapeutics

Switch Therapeutics, a South San Francisco, CA-based, preclinical stage biotechnology company, raised $52M in Series A funding.

The round was led by Insight Partners and UCB Ventures, with participation from existing investors, including Upfront Ventures, BOLD Capital Partners, Eli Lilly and Company, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, PhiFund Ventures.

Led by CEO Dee Datta, and CTO Si-ping Han, Ph.D., Switch Therapeutics is an emerging biotechnology company that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform – based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope – combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. CASi molecules use a small interfering RNA (siRNA) structure with structural extensions to allow for docking to a sensor developed by Switch. The sensor allows efficient delivery of the siRNA while regulating the siRNA’s activity to “switch on” only in selected cells.

The company intends to use the funds to select and advance a development candidate for its lead program for the treatment of a central nervous system disease, explore opportunities to expand its CASi platform into new areas through potential pharmaceutical collaborations, and recruit top R&D and corporate talent to help accelerate its growth

FinSMEs

14/03/2023